Customized In Vivo Ocular Models ace

Customized Rabbit Models of Retinal Neovascularization

DL-2-Aminoadipic acid (DL-AAA) has been widely shown to induce retinal neovascularization and chronic retinal vascular leakage in rabbits. As an expert in ophthalmic pharmacology, Ace Therapeutics has successfully developed a DL-AAA-induced retinal neovascularization model in rabbits that have been verified through extensive experiments. This model resembles patients with advanced wet or exudative age-related macular degeneration (AMD or ARMD) and can be used to evaluate anti-angiogenic and anti-inflammatory therapies for ocular vascular disease.

Rabbit Models of DL-AAA-Induced Retinal Neovascularization

Advantages of Rabbits in Studying Retinal Neovascularization

Retinal angiogenesis is a crucial factor affecting blood vessel development and pathological conditions such as Neovascularization. These pathological conditions can lead to partial or complete vision loss, such as neovascular age-related macular degeneration (nAMD), neovascular glaucoma, corneal neovascularization, and diabetic retinopathy (DR). Anti-VEGF therapy is currently being used clinically to combat this condition with significant success, revolutionizing the treatment of ocular vascular disease. However, anti-VEGF still has certain limitations. Therefore, there is a need to discover and develop improved therapies for retinal vascular diseases, which is an urgent need for large-eyed animal models that can mimic the chronic phenotype of human ocular vascular diseases. Compared with rodents, the large eyes of rabbits provide an excellent condition for such studies and are an ideal biological model. In addition, the central retinal vasculature in rabbits covers an area devoid of the neural retina, maintaining apparent vision even when chemically induced to produce significant vascular leakiness and retinal leakiness.

Fig. 1. Funduscopic and tomographic features of DL-AAA model. (Kumar S, et al., 2022)

Service Overview

DL-2-Aminoadipic acid (DL-AAA) is a retinal glial cytotoxin that causes retinal leakage and neovascularization after intravitreal administration in rabbits. In order to reflect this retinal degeneration situation, while providing our customers with a reliable tool to explore potential anti-angiogenic therapies, Ace Therapeutics successfully establish a DL-AAA-induced retinal neovascularization model in rabbits, which simulates human wet AMD, similar to the late neovascularization stage.

Explore Ace Therapeutics' Rabbit Models of DL-AAA-Induced Retinal Neovascularization

Our DL-AAA-induced rabbit retinal neovascularization model was obtained after a single intravitreal injection of DL-α-aminoadipic acid (AAA) in rabbits, followed up for 12 weeks to 24 months. This model is a chronic retinal neovascularization model, which is capable of reproducing retinal neovascularization angiographic features. Our clients have used it extensively to evaluate anti-angiogenic and anti-inflammatory therapies for ocular vascular disease.

Model characteristics: After DL-AAA treatment in rabbits, new blood vessels grow out of the central retinal vasculature and remain permeable. Specifically manifested by retinal vascular leakage with retinal hemorrhage and retinal hemorrhage that can be observed at 2 weeks growth of neovascularization (RNV), retinal neovascularization was still tortuous and dilated in all eyes at week 8 and continued to extend, and at week 12 the neovascularization was still tortuous and dilated and strong vascular leakage was observed.

Importantly, in order to fully implement and verify the reliability of the DL-AAA-induced rabbit retinal neovascularization model, our scientists also select representative clinically relevant compounds, bevacizumab and ranibizumab, to test the efficacy.

Available Support Services

To visually assess retinal leakage and evaluate the efficacy of antivascular therapy and anti-inflammatory drugs in the DL-AAA rabbit model, Ace Therapeutics offers a range of available support services, including but not limited to:

Slit lamp examination.
In vivo imaging (fundus fluorescein angiography (FFA)).
Flash electroretinogram (fERG).
Histology: retinal morphology and thickness.

Ace Therapeutics aims to provide a powerful analytical tool to help our global customers explore the pathogenesis of wet AMD and test potential anti-vascular or anti-inflammatory therapies. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!

References

Kumar S, Quach J, Cook N, et al. Characterization and validation of a chronic retinal neovascularization rabbit model by evaluating the efficacy of anti-angiogenic and anti-inflammatory drugs. Int J Ophthalmol. 2022, 15(1):15-22.

For Research Use Only.

Get in Touch